Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility

  Teva Signs New $3.0 Billion Syndicated Revolving Credit Facility

            New Facility to Replace Existing $2.5 Billion Facility

           Secures Teva's Liquidity through Revolving Credit Lines

Business Wire

JERUSALEM -- December 18, 2012

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it has
entered into a new five-year, $3.0 billion unsecured revolving credit
facility, which replaces its existing $2.5 billion credit facility.

“By signing this new revolving credit facility, with its increased size and
extended term, we took another step on our recently announced new strategy and
secured ample liquidity to support Teva's future growth," stated Eyal Desheh,
Executive Vice President and Chief Financial Officer of Teva. “We were very
pleased to see the significant oversubscription, demonstrating the strong
desire from our relationship banks, as well as from additional new banks, to
commit to this new facility.”

Citi and HSBC Bank plc are Coordinating Bookrunners and Mandated Lead
Arrangers for the facility. The syndicate also includes Barclays Bank PLC, BNP
Paribas, Credit Suisse Securities (USA) LLC, Goldman Sachs Bank USA, J.P.
Morgan Limited and Morgan Stanley Senior Funding, Inc. as Bookrunners and
Mandated Lead Arrangers, and Bank Leumi le-Israel B.M, DNB Bank ASA, PNC Bank
and RBC Capital Markets as Lead Arrangers.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic drug
maker, with a global product portfolio of more than 850 molecules and a direct
presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $18.3 billion in net revenues in 2011.

Teva’s Safe Harbor Statement under the U.S. Private Securities Litigation
Reform Act of 1995:

This release contains forward-looking statements, which express the current
beliefs and expectations of management. Such statements are based on
management’s current beliefs and expectations and involve a number of known
and unknown risks and uncertainties that could cause our future results,
performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to such
differences include risks relating to: our ability to develop and
commercialize additional pharmaceutical products, competition from the
introduction of competing generic equivalents and the impact of increased
governmental pricing pressures, the effects of competition on revenues of our
innovative products, especially Copaxone® (including competition from
innovative orally-administered alternatives, as well as from potential generic
equivalents), potential liability for revenues of generic products prior to a
final resolution of outstanding patent litigation, including that relating to
the generic version of Protonix®, the extent to which we may obtain U.S.
market exclusivity for certain of our new generic products, the extent to
which any manufacturing or quality control problems damage our reputation for
high quality production and require costly remediation, our ability to
identify, consummate and successfully integrate acquisitions (including the
acquisition of Cephalon), our ability to achieve expected results through our
innovative R&D efforts, dependence on the effectiveness of our patents and
other protections for innovative products, intense competition in our
specialty pharmaceutical businesses, uncertainties surrounding the legislative
and regulatory pathway for the registration and approval of
biotechnology-based products, our potential exposure to product liability
claims to the extent not covered by insurance, any failures to comply with the
complex Medicare and Medicaid reporting and payment obligations, our exposure
to currency fluctuations and restrictions as well as credit risks, the effects
of reforms in healthcare regulation and pharmaceutical pricing and
reimbursement, adverse effects of political or economical instability, major
hostilities or acts of terrorism on our significant worldwide operations,
increased government scrutiny in both the U.S. and Europe of our agreements
with brand companies, interruptions in our supply chain or problems with our
information technology systems that adversely affect our complex manufacturing
processes, the impact of continuing consolidation of our distributors and
customers, the difficulty of complying with U.S. Food and Drug Administration,
European Medicines Agency and other regulatory authority requirements,
potentially significant impairments of intangible assets and goodwill,
potential increases in tax liabilities resulting from challenges to our
intercompany arrangements, the termination or expiration of governmental
programs or tax benefits, any failure to retain key personnel or to attract
additional executive and managerial talent, environmental risks and other
factors that are discussed in our Annual Report on Form 20F for the year ended
December 31, 2011 and in our other filings with the U.S. Securities and
Exchange Commission.

Contact:

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
Joseph Marczely, 267-468-4281
or
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
Israel
Hadar Vismunski-Weinberg, 972 (3) 926-7687
or
United States
Denise Bradley, 215-591-8974